X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-02-18 | AMGN | Amgen Inc | Miller Derek | SVP, HR | S - Sale+OE | $293.45 | -2,024 | 8,544 | -19% | -$593,934 | |||||
| DM | 2025-02-18 | SRRK | Scholar Rock Holding Corp | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | S - Sale+OE | $37.37 | -72,645 | 111,084 | -40% | -$2,714,767 | |||||
2025-02-18 | RCUS | Arcus Biosciences, Inc. | Gilead Sciences, Inc. | 10% | P - Purchase | $11.00 | +1,363,636 | 31,424,760 | +5% | +$14,999,996 | ||||||
| M | 2025-02-18 | CELZ | Creative Medical Technology Holdings, Inc. | Finger Michael H. | Dir | S - Sale | $5.38 | -1,500 | 351 | -81% | -$8,063 | |||||
2025-02-18 | SRRK | Scholar Rock Holding Corp | Parlavecchio Caryn | CHRO | S - Sale | $36.83 | -5,296 | 140,258 | -4% | -$195,046 | ||||||
2025-02-18 | SRRK | Scholar Rock Holding Corp | Myles Edward H | COO, CFO | S - Sale | $36.83 | -7,809 | 140,740 | -5% | -$287,598 | ||||||
2025-02-18 | SRRK | Scholar Rock Holding Corp | Ho Junlin | GC | S - Sale | $36.83 | -5,742 | 189,295 | -3% | -$211,472 | ||||||
2025-02-18 | SRRK | Scholar Rock Holding Corp | Backstrom Jay T. | CEO | S - Sale | $36.83 | -18,372 | 311,991 | -6% | -$676,622 | ||||||
2025-02-18 | NMRA | Neumora Therapeutics, Inc. | Berns Paul L | See Remarks | S - Sale | $1.69 | -13,871 | 7,804,295 | 0% | -$23,468 | ||||||
2025-02-18 | NMRA | Neumora Therapeutics, Inc. | Milligan Michael Lee | See Remarks | S - Sale | $1.69 | -1,978 | 22,470 | -8% | -$3,351 | ||||||
2025-02-18 | NMRA | Neumora Therapeutics, Inc. | Aurora Daljit Singh | Chief Strategy Officer | S - Sale | $1.68 | -8,565 | 203,638 | -4% | -$14,347 | ||||||
2025-02-18 | NMRA | Neumora Therapeutics, Inc. | Lenz Robert A. | Head of R, D | S - Sale | $1.67 | -5,614 | 309,092 | -2% | -$9,383 | ||||||
2025-02-18 | NMRA | Neumora Therapeutics, Inc. | Pinto Joshua | Pres | S - Sale | $1.67 | -8,048 | 215,917 | -4% | -$13,477 | ||||||
2025-02-18 | ALLO | Allogene Therapeutics, Inc. | Messemer Deborah M. | Dir | S - Sale | $2.43 | -13,313 | 144,316 | -8% | -$32,351 | ||||||
2025-02-18 | BEAM | Beam Therapeutics Inc. | Cavanagh Bethany J | SVP, Finance, Treasurer | S - Sale | $35.00 | -6,287 | 37,527 | -14% | -$220,045 | ||||||
| D | 2025-02-19 | VCEL | Vericel Corp | Siegal Jonathan | Principal Accounting Officer | S - Sale+OE | $56.72 | -1,710 | 1,206 | -59% | -$96,991 | |||||
2025-02-18 | IPSC | Century Therapeutics, Inc. | Pfeiffenberger Brent | Pres, CEO | S - Sale | $0.78 | -34,712 | 1,192,545 | -3% | -$27,179 | ||||||
| D | 2025-02-14 | EXEL | Exelixis, Inc. | Beckerle Mary C | Dir | S - Sale+OE | $34.88 | -12,210 | 30,406 | -29% | -$425,878 | |||||
| D | 2025-02-14 | EXEL | Exelixis, Inc. | Poste George | Dir | S - Sale+OE | $34.74 | -15,874 | 169,020 | -9% | -$551,463 | |||||
| D | 2025-02-14 | EXEL | Exelixis, Inc. | Freire Maria C | Dir | S - Sale+OE | $34.94 | -44,114 | 91,007 | -33% | -$1,541,343 | |||||
| D | 2025-02-14 | EXEL | Exelixis, Inc. | Eckhardt Sue Gail | Dir | S - Sale+OE | $35.02 | -11,568 | 30,406 | -28% | -$405,111 | |||||
2025-02-18 | VIR | Vir Biotechnology, Inc. | Scangos George A | Dir | S - Sale | $9.81 | -10,964 | 3,823,584 | 0% | -$107,575 | ||||||
| D | 2025-02-18 | PCVX | Vaxcyte, Inc. | Guggenhime Andrew | Pres, CFO | S - Sale+OE | $83.85 | -8,000 | 109,491 | -7% | -$670,823 | |||||
| DM | 2025-02-18 | CRSP | Crispr Therapeutics AG | Kulkarni Samarth | CEO | S - Sale+OE | $54.21 | -18,568 | 275,595 | -6% | -$1,006,580 | |||||
| D | 2025-02-19 | CRSP | Crispr Therapeutics AG | Bruno Julianne | COO | S - Sale+OE | $52.80 | -333 | 14,150 | -2% | -$17,582 | |||||
| DM | 2025-02-18 | CRSP | Crispr Therapeutics AG | Kasinger James R. | GC, Secretary | S - Sale+OE | $53.67 | -11,542 | 74,880 | -13% | -$619,492 | |||||
2025-02-14 | SWTX | Springworks Therapeutics, Inc. | Islam Saqib | CEO | S - Sale | $59.92 | -10,672 | 1,063,953 | -1% | -$639,490 | ||||||
2025-02-14 | SWTX | Springworks Therapeutics, Inc. | Lynch Daniel | Dir | S - Sale | $60.00 | -400 | 130,544 | 0% | -$24,000 | ||||||
2025-02-18 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale | $104.09 | -2,500 | 169,061 | -1% | -$260,225 | ||||||
2025-02-18 | SLDB | Solid Biosciences Inc. | Adage Capital Management, L.P. | 10% | P - Purchase | $7.56 | +252,545 | 4,248,084 | +6% | +$1,909,240 | ||||||
| D | 2025-02-18 | CGON | Cg Oncology, Inc. | Post Leonard E | Dir | S - Sale+OE | $28.61 | -1,000 | 0 | -100% | -$28,610 | |||||
| D | 2025-02-14 | BEAM | Beam Therapeutics Inc. | Bellon Christine | GC | S - Sale+OE | $34.00 | -10,000 | 102,968 | -9% | -$340,000 | |||||
| DM | 2025-02-13 | ADPT | Adaptive Biotechnologies Corp | Robins Chad M | CEO, COB | S - Sale+OE | $8.47 | -470,368 | 2,576,701 | -15% | -$3,985,754 | |||||
2025-02-18 | AURA | Aura Biosciences, Inc. | Plavsic Mark | CTO | S - Sale | $7.75 | -2,151 | 209,456 | -1% | -$16,670 | ||||||
2025-02-18 | AURA | Aura Biosciences, Inc. | Elazzouzi Amy | SVP, Finance | S - Sale | $7.75 | -1,404 | 82,278 | -2% | -$10,881 | ||||||
2025-02-18 | AURA | Aura Biosciences, Inc. | Hopkins Janet Jill | Chief Medical Officer | S - Sale | $7.75 | -2,534 | 269,794 | -1% | -$19,639 | ||||||
2025-02-18 | AURA | Aura Biosciences, Inc. | De Los Pinos Elisabet | See Remarks | S - Sale | $7.75 | -20,221 | 610,203 | -3% | -$156,796 | ||||||
| D | 2025-02-13 | ECL | Ecolab Inc. | Higgins Arthur J | Dir | S - Sale+OE | $263.05 | -1,800 | 26,535 | -6% | -$473,490 | |||||
| DM | 2025-02-14 | CCCC | C4 Therapeutics, Inc. | Boyle Scott N | Chief Business Officer | S - Sale+OE | $3.15 | -1,159 | 107,805 | -1% | -$3,651 | |||||
| D | 2025-02-14 | TECH | Bio-Techne Corp | Herr Amy E. | Dir | S - Sale+OE | $65.96 | -1,860 | 3,016 | -38% | -$122,691 | |||||
2025-02-13 | VOR | Vor Biopharma Inc. | Attar Eyal C. | Chief Medical Officer | S - Sale | $1.42 | -2,227 | 126,625 | -2% | -$3,162 | ||||||
| D | 2025-02-14 | SLDB | Solid Biosciences Inc. | Hanrahan Jessie | Chief Regulatory Officer | S - Sale+OE | $3.96 | -3,079 | 19,281 | -14% | -$12,193 | |||||
| D | 2025-02-14 | SLDB | Solid Biosciences Inc. | Brooks Gabriel | Chief Medical Officer | S - Sale+OE | $3.96 | -3,256 | 22,812 | -12% | -$12,894 | |||||
| D | 2025-02-14 | SLDB | Solid Biosciences Inc. | Tan Kevin | CFO, Treasurer | S - Sale+OE | $3.96 | -3,164 | 32,250 | -9% | -$12,529 | |||||
| D | 2025-02-14 | SLDB | Solid Biosciences Inc. | Howton David T | COO | S - Sale+OE | $3.96 | -5,561 | 24,789 | -18% | -$22,022 | |||||
| D | 2025-02-14 | SLDB | Solid Biosciences Inc. | Herzich Paul | CTO | S - Sale+OE | $3.96 | -2,688 | 18,388 | -13% | -$10,644 | |||||
| D | 2025-02-14 | SLDB | Solid Biosciences Inc. | Cumbo Alexander | Pres, CEO | S - Sale+OE | $3.96 | -11,365 | 60,717 | -16% | -$45,005 | |||||
| D | 2025-02-14 | SLDB | Solid Biosciences Inc. | Ganot Ilan | Dir | S - Sale+OE | $3.96 | -1,711 | 132,923 | -1% | -$6,776 | |||||
| D | 2025-02-13 | NBIX | Neurocrine Biosciences Inc | Cooke Julie | CHRO | S - Sale+OE | $116.78 | -1,551 | 20,190 | -7% | -$181,129 | |||||
| D | 2025-02-13 | NBIX | Neurocrine Biosciences Inc | Gorman Kevin Charles | Dir | S - Sale+OE | $116.69 | -5,844 | 524,209 | -1% | -$681,914 | |||||
2025-02-13 | NBIX | Neurocrine Biosciences Inc | Sherwin Stephen A | Dir | S - Sale | $116.69 | -13,831 | 10,673 | -56% | -$1,613,923 | ||||||
| DM | 2025-02-13 | NBIX | Neurocrine Biosciences Inc | Roberts Eiry | Chief Medical Officer | S - Sale+OE | $116.44 | -2,218 | 35,640 | -6% | -$258,264 | |||||
2025-02-13 | VIR | Vir Biotechnology, Inc. | Sabatini Brent | SVP, Chief Accounting Officer | S - Sale | $9.15 | -1,562 | 28,189 | -5% | -$14,291 | ||||||
| D | 2025-02-13 | NBIX | Neurocrine Biosciences Inc | Onyia Jude | Chief Scientific Officer | S - Sale+OE | $116.79 | -2,879 | 18,089 | -14% | -$336,239 | |||||
| D | 2025-02-13 | NBIX | Neurocrine Biosciences Inc | Lippoldt Darin | GC | S - Sale+OE | $116.76 | -2,184 | 43,405 | -5% | -$254,992 | |||||
| D | 2025-02-13 | NBIX | Neurocrine Biosciences Inc | Gano Kyle | CEO | S - Sale+OE | $116.85 | -2,558 | 139,907 | -2% | -$298,908 | |||||
| D | 2025-02-13 | NBIX | Neurocrine Biosciences Inc | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $116.71 | -1,471 | 4,730 | -24% | -$171,674 | |||||
| D | 2025-02-14 | FENC | Fennec Pharmaceuticals Inc. | Rallis Chris A | Dir | S - Sale+OE | $6.82 | -1,186 | 53,020 | -2% | -$8,089 | |||||
| D | 2025-02-13 | NBIX | Neurocrine Biosciences Inc | Boyer David W. | Chief Corp. Affairs Officer | S - Sale+OE | $116.74 | -1,785 | 3,565 | -33% | -$208,387 | |||||
| D | 2025-02-13 | NBIX | Neurocrine Biosciences Inc | Benevich Eric | Chief Commercial Officer | S - Sale+OE | $116.73 | -2,154 | 44,689 | -5% | -$251,428 | |||||
| D | 2025-02-13 | NBIX | Neurocrine Biosciences Inc | Abernethy Matt | CFO | S - Sale+OE | $116.86 | -2,558 | 35,810 | -7% | -$298,923 | |||||
| M | 2024-05-17 | XFOR | X4 Pharmaceuticals, Inc | Baldry Mark | Chief Commercial Officer | P - Purchase | $0.55 | +35,050 | 729,173 | +5% | +$19,252 | |||||
| D | 2025-02-12 | VCEL | Vericel Corp | McLaughlin Kevin F | Dir | S - Sale+OE | $55.46 | -7,000 | 11,900 | -37% | -$388,250 | |||||
| D | 2025-02-12 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale+OE | $102.22 | -137,676 | 171,223 | -45% | -$14,073,241 | |||||
2025-02-11 | AMGN | Amgen Inc | Gordon Murdo | EVP, Global Commercial Ops | S - Sale | $294.80 | -8,771 | 44,186 | -17% | -$2,585,644 | ||||||
| M | 2025-02-11 | RLAY | Relay Therapeutics, Inc. | Patel Sanjiv | Pres, CEO | S - Sale | $3.80 | -215,506 | 1,769,992 | -11% | -$818,400 | |||||
2025-02-11 | ZEOX | Zeo Scientifix, Inc. | Skycrest Holdings, LLC | Former 10% Owner | P - Purchase | $3.19 | +5,000 | 312,687 | +2% | +$15,960 | ||||||
| D | 2025-02-10 | SWTX | Springworks Therapeutics, Inc. | Pichl Daniel | Chief People Officer | S - Sale+OE | $54.36 | -29,750 | 50,762 | -37% | -$1,617,329 | |||||
2025-02-10 | SWTX | Springworks Therapeutics, Inc. | Lynch Daniel | Dir | S - Sale | $54.46 | -175,000 | 130,944 | -57% | -$9,530,351 | ||||||
2025-02-10 | SWTX | Springworks Therapeutics, Inc. | Islam Saqib | CEO | S - Sale | $53.30 | -48,000 | 1,002,502 | -5% | -$2,558,237 | ||||||
| D | 2025-02-10 | SWTX | Springworks Therapeutics, Inc. | Hambleton Julie | Dir | S - Sale+OE | $53.01 | -13,774 | 4,095 | -77% | -$730,207 | |||||
2025-02-10 | SWTX | Springworks Therapeutics, Inc. | Edris Badreddin | COO | S - Sale | $53.13 | -30,000 | 189,712 | -14% | -$1,593,795 | ||||||
| D | 2025-02-10 | NBIX | Neurocrine Biosciences Inc | Cooke Julie | CHRO | S - Sale+OE | $118.28 | -700 | 18,831 | -4% | -$82,793 | |||||
| D | 2025-02-10 | NBIX | Neurocrine Biosciences Inc | Gorman Kevin Charles | Dir | S - Sale+OE | $118.37 | -2,274 | 519,074 | 0% | -$269,167 | |||||
| D | 2025-02-10 | NBIX | Neurocrine Biosciences Inc | Roberts Eiry | Chief Medical Officer | S - Sale+OE | $118.22 | -980 | 33,253 | -3% | -$115,853 | |||||
| D | 2025-02-10 | NBIX | Neurocrine Biosciences Inc | Lippoldt Darin | GC | S - Sale+OE | $118.25 | -911 | 41,679 | -2% | -$107,727 | |||||
| D | 2025-02-10 | NBIX | Neurocrine Biosciences Inc | Gano Kyle | CEO | S - Sale+OE | $118.39 | -980 | 137,658 | -1% | -$116,020 | |||||
| D | 2025-02-10 | NBIX | Neurocrine Biosciences Inc | Boyer David W. | Chief Corp. Affairs Officer | S - Sale+OE | $118.31 | -700 | 1,998 | -26% | -$82,820 | |||||
| D | 2025-02-10 | NBIX | Neurocrine Biosciences Inc | Benevich Eric | Chief Commercial Officer | S - Sale+OE | $118.31 | -980 | 42,799 | -2% | -$115,940 | |||||
| D | 2025-02-10 | NBIX | Neurocrine Biosciences Inc | Abernethy Matt | CFO | S - Sale+OE | $118.27 | -980 | 33,561 | -3% | -$115,909 | |||||
2025-02-10 | VOR | Vor Biopharma Inc. | Attar Eyal C. | Chief Medical Officer | S - Sale | $1.37 | -2,554 | 128,852 | -2% | -$3,499 | ||||||
2025-02-11 | VYGR | Voyager Therapeutics, Inc. | Carter Todd Alfred | Chief Scientific Officer | S - Sale | $4.45 | -5,413 | 81,023 | -6% | -$24,088 | ||||||
| D | 2025-02-11 | PASG | Passage Bio, Inc. | Borthwick Kathleen | CFO | S - Sale+OE | $0.53 | -3,183 | 41,283 | -7% | -$1,686 | |||||
2025-02-11 | VYGR | Voyager Therapeutics, Inc. | Swartz Robin | COO, CBO | S - Sale | $4.45 | -6,950 | 102,291 | -6% | -$30,928 | ||||||
2025-02-11 | VYGR | Voyager Therapeutics, Inc. | Sandrock Alfred | Pres, CEO | S - Sale | $4.45 | -16,644 | 308,518 | -5% | -$74,066 | ||||||
2025-02-11 | VYGR | Voyager Therapeutics, Inc. | Fahey Sandell Jacquelyn | GC | S - Sale | $4.45 | -4,358 | 81,643 | -5% | -$19,393 | ||||||
| M | 2025-02-04 | HLVX | Hillevax, Inc. | Hershberg Robert | See Remarks | S - Sale | $1.83 | -26,535 | 1,101,498 | -2% | -$48,661 | |||||
| M | 2025-02-04 | HLVX | Hillevax, Inc. | Maltbie Shane | CFO | S - Sale | $1.82 | -8,291 | 79,887 | -9% | -$15,117 | |||||
2025-02-07 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $2.48 | +600 | 107,920 | +1% | +$1,488 | ||||||
2025-02-07 | TWST | Twist Bioscience Corp | Chess Robert | Dir | S - Sale | $53.14 | -2,940 | 60,701 | -5% | -$156,217 | ||||||
| D | 2025-02-07 | AMGN | Amgen Inc | Graham Jonathan P | EVP, Gen. Counsel, Secy. | S - Sale+OE | $293.12 | -25,045 | 28,987 | -46% | -$7,341,123 | |||||
| D | 2025-02-05 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Chief Medical Officer | S - Sale+OE | $40.69 | -3,520 | 252,623 | -1% | -$143,229 | |||||
2025-02-05 | APGE | Apogee Therapeutics, Inc. | Henderson Michael Thomas | CEO | S - Sale | $40.58 | -15,000 | 1,302,987 | -1% | -$608,700 | ||||||
2025-02-05 | TECX | Tectonic Therapeutic, Inc. | Springer Timothy A | Dir, 10% | P - Purchase | $50.68 | +789,294 | 5,382,415 | +17% | +$39,999,977 | ||||||
2025-02-05 | TECX | Tectonic Therapeutic, Inc. | Lochner Daniel | CFO | P - Purchase | $54.14 | +4,617 | 4,617 | New | +$249,964 | ||||||
| D | 2025-02-05 | VCEL | Vericel Corp | Zerbe Robert L Md | Dir | S - Sale+OE | $62.50 | -2,500 | 26,595 | -9% | -$156,250 | |||||
| DM | 2025-02-05 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $7.90 | -40,000 | 1,273,156 | -3% | -$316,000 | |||||
| D | 2025-02-05 | VCEL | Vericel Corp | Siegal Jonathan | Principal Accounting Officer | S - Sale+OE | $61.99 | -1,092 | 1,206 | -48% | -$67,693 | |||||
| D | 2025-02-05 | PCVX | Vaxcyte, Inc. | Eydelman Mikhail | SVP, GC, Corp Sec | S - Sale+OE | $90.07 | -5,000 | 28,222 | -15% | -$450,369 | |||||
2025-02-05 | AMGN | Amgen Inc | Grygiel Nancy A. | SVP, CCO | S - Sale | $304.47 | -1,589 | 7,312 | -18% | -$483,808 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |